Oracle Autonomous Health Framework up to 26.8 Trace File Analyzer privileges management
| CVSS Meta Temp Score | Current Exploit Price (≈) | CTI Interest Score |
|---|---|---|
| 8.1 | $0-$5k | 0.00- |
Summary
A vulnerability, which was classified as very critical, was found in Oracle Autonomous Health Framework up to 26.8. Impacted is an unknown function of the component Trace File Analyzer. Executing a manipulation can lead to privileges management. This vulnerability appears as CVE-2026-101478. The attack requires local access. There is no available exploit. You should upgrade the affected component.
Details
A vulnerability classified as very critical was found in Oracle Autonomous Health Framework up to 26.8. This vulnerability affects some unknown functionality of the component Trace File Analyzer. The manipulation with an unknown input leads to a privileges management vulnerability. The CWE definition for the vulnerability is CWE-269. The product does not properly assign, modify, track, or check privileges for an actor, creating an unintended sphere of control for that actor. As an impact it is known to affect confidentiality, integrity, and availability. CVE summarizes:
Vulnerability in Oracle Autonomous Health Framework (component: Trace File Analyzer). Supported versions that are affected are 26.3-26.8. Easily exploitable vulnerability allows low privileged attacker with logon to the infrastructure where Oracle Autonomous Health Framework executes to compromise Oracle Autonomous Health Framework. Successful attacks of this vulnerability can result in takeover of Oracle Autonomous Health Framework. CVSS 3.1 Base Score 7.8 (Confidentiality, Integrity and Availability impacts). CVSS Vector: (CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H).
The advisory is shared for download at oracle.com. This vulnerability was named CVE-2026-101478 since 09/28/2026. The exploitation appears to be easy. The attack needs to be approached locally. There are neither technical details nor an exploit publicly available. The current price for an exploit might be approx. USD $0-$5k (estimation calculated on 10/21/2026). The MITRE ATT&CK project declares the attack technique as T1068.
Upgrading eliminates this vulnerability.
VulDB is the best source for vulnerability data and more expert information about this specific topic.
Product
Vendor
Name
Version
License
Website
- Vendor: https://www.oracle.com
CPE 2.3
CPE 2.2
CVSSv4
VulDB Vector: 🔒VulDB Reliability: 🔍
CVSSv3
VulDB Meta Base Score: 8.3VulDB Meta Temp Score: 8.1
VulDB Base Score: 8.8
VulDB Temp Score: 8.4
VulDB Vector: 🔒
VulDB Reliability: 🔍
CNA Base Score: 7.8
CNA Vector (oracle): 🔒
CVSSv2
| AV | AC | Au | C | I | A |
|---|---|---|---|---|---|
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| Vector | Complexity | Authentication | Confidentiality | Integrity | Availability |
|---|---|---|---|---|---|
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
VulDB Base Score: 🔒
VulDB Temp Score: 🔒
VulDB Reliability: 🔍
Exploiting
Class: Privileges managementCWE: CWE-269 / CWE-266
CAPEC: 🔒
ATT&CK: 🔒
Physical: Partially
Local: Yes
Remote: No
Availability: 🔒
Status: Not defined
Price Prediction: 🔍
Current Price Estimation: 🔒
| 0-Day | Unlock | Unlock | Unlock | Unlock |
|---|---|---|---|---|
| Today | Unlock | Unlock | Unlock | Unlock |
Threat Intelligence
Interest: 🔍Active Actors: 🔍
Active APT Groups: 🔍
Countermeasures
Recommended: UpgradeStatus: 🔍
0-Day Time: 🔒
Timeline
09/28/2026 CVE reserved10/20/2026 VulDB entry created
10/21/2026 Advisory disclosed
10/21/2026 VulDB entry last update
Sources
Vendor: oracle.comAdvisory: oracle.com
Status: Confirmed
CVE: CVE-2026-101478 (🔒)
GCVE (CVE): GCVE-0-2026-101478
GCVE (VulDB): GCVE-100-423208
Entry
Created: 10/21/2026 00:30Changes: 10/21/2026 00:30 (64)
Complete: 🔍
Cache ID: 216::103
VulDB is the best source for vulnerability data and more expert information about this specific topic.
No comments yet. Languages: en.
Please log in to comment.